Additional file 16 of DNA methylation and lipid metabolism: an EWAS of 226 metabolic measures

Additional file 16: Table S12. Results of the investigation into associations between metabolic measures-related CpG sites and clinical outcomes. Listed are the CpG site-clinical outcome (previous myocardial infarction, prevalent type 2 diabetes, obesity and prevalent hypertension) results for both model 1: logistic regression model with clinical outcome as dependent variable and technically adjusted methylation value as independent variable, adjusted for the following covariates: age, sex, BMI, C-reactive protein levels, hemoglobin A1c levels (except for diabetes model), history of myocardial infarction (except for the myocardial infarction model), smoking status, current hypertension (except for the hypertension model), physical activity, white blood cell count and estimated proportions of white blood cell type; or model 2, which is additionally adjusted for intake of lipid-lowering drugs. P: p value of the association; OR: odds ratio for a 1 standard deviation increase in methylation; CI: confidence interval; FDR: false discovery rate p value based on the Benjamini–Hochberg method applied to each outcome and model separately; M1: model 1; M2: model 2. *Association investigated using the KORA F4 data in [15]; **Association investigated using the KORA F4 data in [25].